Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents

Immunotherapy has recently emerged as a novel strategy for treating different types of solid tumors, with promising results. However, still a large fraction of patients do not primarily respond to such approaches, and even responders sooner or later develop resistance. Moreover, immunotherapy is a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciciola, Paola, Cascetta, Priscilla, Bianco, Cataldo, Formisano, Luigi, Bianco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141336/
https://www.ncbi.nlm.nih.gov/pubmed/32138216
http://dx.doi.org/10.3390/jcm9030675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141336/
https://www.ncbi.nlm.nih.gov/pubmed/32138216
http://dx.doi.org/10.3390/jcm9030675

Ejemplares similares